Geriatric Exclusivity For Cancer Drugs Could Drive Needed Research – IoM Report
This article was originally published in The Pink Sheet Daily
Executive Summary
In a report that offers a number of recommendations related to cancer care, an IoM committee suggests a plan for awarding six months of added patent life to new cancer drugs that are studied in the elderly.
You may also be interested in...
Geriatric Exclusivity? Incentives For Research In Elderly Debated At National Academies Workshop
FDA principal deputy commissioner Amy Abernethy and former commissioner Robert Califf point to success of orphan drug and pediatric exclusivity incentives in spurring drug development for neglected populations.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.